Singapore markets open in 4 hours 7 minutes

Alnylam Pharmaceuticals, Inc. (0HD2.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
151.78+3.19 (+2.15%)
At close: 06:18PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.41
52-week change 3-18.85%
S&P500 52-week change 329.31%
52-week high 3217.98
52-week low 3143.66
50-day moving average 3170.73
200-day moving average 3180.79

Share statistics

Avg vol (3-month) 31.44k
Avg vol (10-day) 3346
Shares outstanding 5101.03M
Implied shares outstanding 6N/A
Float 8125.96M
% held by insiders 10.41%
% held by institutions 192.54%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin -16.58%
Operating margin (ttm)-8.79%

Management effectiveness

Return on assets (ttm)-3.05%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)2B
Revenue per share (ttm)15.97
Quarterly revenue growth (yoy)54.80%
Gross profit (ttm)N/A
EBITDA -122.3M
Net income avi to common (ttm)-332.08M
Diluted EPS (ttm)-7.49
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.37B
Total cash per share (mrq)18.75
Total debt (mrq)2.68B
Total debt/equity (mrq)N/A
Current ratio (mrq)3.17
Book value per share (mrq)-1.73

Cash flow statement

Operating cash flow (ttm)189.12M
Levered free cash flow (ttm)172.9M